CochLear (OTCMKTS:CHEOY – Get Free Report) and Sonic Healthcare (OTCMKTS:SKHHY – Get Free Report) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.
Analyst Recommendations
This is a summary of current recommendations for CochLear and Sonic Healthcare, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CochLear | 0 | 2 | 1 | 2 | 3.00 |
| Sonic Healthcare | 1 | 0 | 1 | 0 | 2.00 |
Sonic Healthcare has a consensus price target of $30.15, indicating a potential upside of 90.70%. Given Sonic Healthcare’s higher possible upside, analysts plainly believe Sonic Healthcare is more favorable than CochLear.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| CochLear | N/A | N/A | N/A |
| Sonic Healthcare | N/A | N/A | N/A |
Earnings & Valuation
This table compares CochLear and Sonic Healthcare”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CochLear | $1.53 billion | 5.55 | $251.85 million | N/A | N/A |
| Sonic Healthcare | $6.25 billion | 1.25 | $332.61 million | N/A | N/A |
Sonic Healthcare has higher revenue and earnings than CochLear.
Risk & Volatility
CochLear has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Sonic Healthcare has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.
Dividends
CochLear pays an annual dividend of $1.24 per share and has a dividend yield of 1.9%. Sonic Healthcare pays an annual dividend of $0.57 per share and has a dividend yield of 3.6%.
Insider & Institutional Ownership
0.0% of Sonic Healthcare shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Sonic Healthcare beats CochLear on 5 of the 9 factors compared between the two stocks.
About CochLear
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
About Sonic Healthcare
Sonic Healthcare Limited offers medical diagnostic services to medical practitioners, hospitals, community health services, and their collective patients. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions; and radiology services, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. It offers primary care medical services comprising general practice clinics, occupational health services, skin cancer clinics, after-hours general practice services, general practice IT solutions, and community-based healthcare services. The company operates in Australia, the United Kingdom, Ireland, the United States, Germany, Switzerland, New Zealand, Belgium, and internationally. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia.
Receive News & Ratings for CochLear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CochLear and related companies with MarketBeat.com's FREE daily email newsletter.
